Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genenta Science S.p.A.GNTA · Entity 7215 | Director | March 30, 2026 | April 01, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director · President and CEO | June 30, 2022 | July 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genenta Science S.p.A.
Report date March 30, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2035-12-31 | Direct | 20,000 |
Reported balance
After 2026-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-30 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock options vest in equal monthly installments over one year beginning March 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in equal monthly installments over one year beginning March 30, 2026.
SQZ Biotechnologies Co
Report date June 30, 2022 · Filed July 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 287,884 |
Reported balance
After 2022-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-30 · Grant · Acquired 2,436 · Balance 287,884 F1: The reporting person is voluntarily reporting the acquisition on June 30, 2022 of 2,436 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition on June 30, 2022 of 2,436 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed Apr 1, 2026 20:05 UTC | Genenta Science S.p.A. GNTA · Entity 7215 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-014631 · ownership.xml · derivative · entry 1 Sharei Armon · CIK 0001829463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: American Depositary Shares · 20,000 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options vest in equal monthly installments over one year beginning March 30, 2026. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 17:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantCommon Stock | 2,436 | $2.70 | $6,584.51 |
DisclosureSEC source: 0001209191-22-040781 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,884 F1 · balance_after: The reporting person is voluntarily reporting the acquisition on June 30, 2022 of 2,436 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 395,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001209191-22-009831 · doc4.xml · derivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,000 Underlying: Common Stock · 395,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying securities on February 10, 2023 and in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option · Derivative | 13,000 | $1.81 Strike: $1.81 | $23,530.00 |
DisclosureSEC source: 0001209191-22-003218 · doc4.xml · derivative · entry 2 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,937 Underlying: Common Stock · 13,000 shares Expires 2026-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F2 · derivative.exercise_date: The option was originally granted for 286,514 shares. The option vested and became exercisable as to the original share amount as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 13,000 | $1.81 | $23,530.00 |
DisclosureSEC source: 0001209191-22-003218 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantCommon Stock | 1,686 | $7.59 | $12,797.58 |
DisclosureSEC source: 0001209191-22-000983 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,448 F1 · balance_after: The reporting person is voluntarily reporting the acquisition on December 31, 2021 of 1,686 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option · Derivative | 11,049 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-21-070962 · doc4.xml · derivative · entry 2 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,937 Underlying: Common Stock · 11,049 shares Expires 2026-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F2 · derivative.exercise_date: The option was originally granted for 286,514 shares. The option vested and became exercisable as to the original share amount as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 17:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 11,049 | $1.81 | $19,998.69 |
DisclosureSEC source: 0001209191-21-070962 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 17:32 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-21-009031 · doc4.xml · derivative · entry 2 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,986 Underlying: Common Stock · 8,000 shares Expires 2026-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F2 · derivative.exercise_date: The option was originally granted for 286,514 shares. The option vested and became exercisable as to the original share amount as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 17:32 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 8,000 | $1.81 | $14,480.00 |
DisclosureSEC source: 0000899243-21-009031 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 17:48 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0000899243-21-008254 · doc4.xml · derivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying securities on February 23, 2022 and in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:30 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-21-001490 · doc4.xml · derivative · entry 2 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,986 Underlying: Common Stock · 2,500 shares Expires 2026-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F2 · derivative.exercise_date: The option was originally granted for 286,514 shares. The option vested and and became exercisable as to the original share amount as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:30 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 2,500 | $1.81 | $4,525.00 |
DisclosureSEC source: 0000899243-21-001490 · doc4.xml · nonDerivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 18:30 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 105,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029973 · doc4.xml · derivative · entry 1 Sharei Armon · CIK 0001829463 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,300 Underlying: Common Stock · 105,300 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on October 29, 2021 and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.